Trump's aggressive cutting of drug prices may reshuffle the pharmaceutical industry. Citigroup remains bullish on Regeneron Pharmaceuticals (REGN.US) after assessing policy risks.

According to the WiseTrend Financial APP, Citigroup, a financial giant on Wall Street, released its latest research report on the global pharmaceutical industry on Wednesday. The institution announced an upgrade in the stock rating for the American pharmaceutical giant Regeneron Pharmaceuticals (REGN.US) and a downgrade in the stock rating for another pharmaceutical industry leader AbbVie (ABBV.US). The core logic behind this decision lies in the Trump administration's latest policy measures targeting the global pharmaceutical industry, which brings different levels of valuation and fundamental expectations risks to these two American pharmaceutical industry giants.